Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of arthritis and psoriasis.
Vidac Pharma Holding plc has announced the initiation of an in vivo preclinical program to evaluate the potential of its hexokinase 2 (HK2)/voltage-dependent anion channel (VDAC)-targeting approach in psoriasis.
A would-be psoriasis winner began taking more distinct shape in the competitive oral tyrosine kinase 2 (TYK2) inhibitor space, and shares of Alumis Inc. (NASDAQ:ALMS) closed Jan. 6 at $16.23, up $7.92, or 95% – having traded as high as $22.30 – after unveiling positive top-line results from the phase III Onward1 and Onward2 trials with envudeucitinib (envu). Alumis CEO Martin Babler called 2026 “a value-inflection year. It starts today.”
Fibrobiologics Inc. has filed an IND application with the FDA seeking to begin first-in-human trials of CYPS-317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis.
Peptidream Inc. has announced progression of an oral dual IL-17A and IL-17F macrocyclic peptide inhibitor for psoriasis, with the program entering the company’s clinical development portfolio.
Fourteen therapies to treat moderate to severe psoriasis are expected to enter the Chinese market in the next two years, according to Clarivate and BioWorld reports. Eleven of them are being developed by domestic biopharmaceutical firms.
Fourteen therapies to treat moderate to severe psoriasis are expected to enter the Chinese market in the next two years, according to Clarivate and BioWorld reports. Eleven of them are being developed by domestic biopharmaceutical firms.
Haisco Pharmaceutical Group Co. Ltd. has identified compounds acting as TNF-α/TNF receptor superfamily member 1A (TNFR1) interaction inhibitors reported to be useful for the treatment of psoriasis and rheumatoid arthritis.
Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting initiation of the first clinical studies next year.
Fibrobiologics Inc. has announced IND-enabling updates from its psoriasis research program demonstrating the potential of human dermal fibroblast (HDF) spheroids as a novel therapeutic approach for chronic-relapse psoriasis.
